CLS Americas and HALO Diagnostics Initiate Prostate Cancer Clinical Study using TRANBERG Focal Laser Ablation System CLS,and HALO Diagnostics announce 25-patient clinical study using the TRANBERG™ System to perform focal laser ablation on prostate cancer patients.

CLS Americas and HALO Precision Diagnostics Announce 25 Patient Post-Market Study to Evaluate CLS’s TRANBERG Thermal Therapy System IRVINE, Calif. and INDIAN WELLS, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems...

CLS Americas Debuts Office-Based, Fusion-Guided TRANBERG Focal Laser Ablation System at AUA 2022 Conference IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced it will debut its Office-Based, MR/US Fusion-Guided, TRANBERG®...

CLS Americas and URN Announce Clinical Study “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer” IRVINE, Calif. and MIAMI, March 29, 2022 (GLOBE NEWSWIRE) -- CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used...